相关实验视频
Updated: Jun 14, 2025

03:25
Simple Continuous Glucose Monitoring in Freely Moving Mice
Published on: February 24, 2023
5.3K
使用生物标志物检测高血糖,与持续的葡萄糖监测相比
Natalie Rula Daya1, Michael Fang1, Jung-Im Shin1
1Department of Epidemiology and the Welch Center for Prevention, Epidemiology and Clinical Research, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD.
Diabetes care
|June 12, 2025
概括
糖化白蛋白和果糖胺在反映连续葡萄糖监测 (CGM) 数据时,与血红蛋白A1c表现相似,用于2型糖尿病管理. 这些生物标志物为评估高血糖和血糖控制提供了可行的替代方案.
科学领域:
- 内分泌学 在内分泌学.
- 代谢疾病 代谢疾病
- 临床化学 临床化学
背景情况:
- 持续血糖监测 (CGM) 提供了详细的血糖洞察力.
- 像血红蛋白A1c (HbA1c) 这样的传统生物标志物在反映短期葡萄糖波动方面存在局限性.
研究的目的:
- 为了与CGM指标比较糖性白蛋白,果糖胺和1,5-无糖醇 (1,5-AG).
- 为了评估它们与高血糖和血糖控制在2型糖尿病中的一致性.
主要方法:
- 对552名患有2型糖尿病的成年人进行了综合横截面分析.
- 参与者使用CGM长达2周.
- 评估了血液生物标志物和CGM指标之间的一致性.
主要成果:
- CGM平均葡萄糖与HbA1c (r=0.72),糖化白蛋白 (r=0.64) 和果糖胺 (r=0.64) 有很强的相关性,但与1,5-AG (r=0.46) 有很弱的相关性.
- 糖化专和果糖胺在检测范围内及以上时间方面表现与HbA1c相似 (c-统计0.85-0.94).
结论:
- 糖化白蛋白和果糖胺与CGM定义的高血糖度量很好地一致,与HbA1c.c.相当.
- 这些生物标志物在评估时间范围内的和超越范围时是有效的.
- 糖化白蛋白和果糖胺是高血糖评估的有价值的替代措施.
相关概念视频
Hypoglycemia and Glucagon
216
Without prolonged fasting, healthy individuals maintain blood glucose levels above 3.5 mM due to a well-adapted neuroendocrine counterregulatory system that effectively prevents acute hypoglycemia, a potentially life-threatening condition. The primary clinical scenarios for hypoglycemia encompass diabetes treatment, inappropriate production of endogenous insulin or insulin-like substances by tumors, and the use of glucose-lowering agents in non-diabetic individuals. Notably, hypoglycemia in the...
216
Diabetes: Symptoms, Diagnosis, and Complications
520
For most patients, experiencing several weeks of polyuria, polydipsia, fatigue, and significant weight loss may indicate the presence of diabetes. Furthermore, adults displaying the phenotypic appearance of type 2 diabetes (particularly those who are obese and not initially insulin-requiring), may have islet cell autoantibodies, suggesting autoimmune-mediated β cell destruction and a diagnosis of latent autoimmune diabetes of adults (LADA). The categorization of glucose homeostasis is...
520
Hormones Regulating Blood Glucose
3.1K
Insulin is released by beta cells of the pancreas when blood glucose levels are high. It facilitates glucose absorption and utilization in insulin-dependent cells with insulin receptors on their plasma membranes. Insulin promotes glucose uptake by increasing the number of glucose transport proteins in the cell membrane, allowing glucose to enter the cell. As a result, glucose utilization and ATP production are enhanced.
In addition to accelerating glucose uptake and utilization, insulin has...
In addition to accelerating glucose uptake and utilization, insulin has...
3.1K
Diabetes Mellitus: Type 2 and Gestational
2.3K
Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
2.3K
Diabetes: Management and Pharmacotherapy
245
The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
245
Oral Hypoglycemic Agents: Glinides
147
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
147

